
    
      This is a randomized,controlled,prospective,open,multi-center clinical trial,amied to
      evaluate the safety, tolerability,and efficacy of decitabine combined with R±DHAP in replase
      and refractory Diffuse Large B cell lymphoma.A total of 60 patients are planned to be
      enrolled into the study.Patients with diagnosis of replase and refractory Diffuse Large B
      cell lymphoma will be into two groups,and be treated with decitabine pluse R±DHAP or only
      R±DHAP,respectively.The primary end points are objective responder rate(ORR) and time to
      progression(TTP) and the secondary end points include overall survival(OS) and progression
      free survival(PFS).
    
  